ParAllele BioScience Products & Services


The ParAllele Advantage People Board of Directors Scientific Advisory Board Management Team History News Events Alliances	Board of Directors Thomas D. Willis, CSO and co-founder Dr. Willis has spearheaded ParAllele's successful licensing and financing activities since the company's founding. Prior to founding ParAllele, Dr. Willis served as Associate Director of the Stanford Genome Technology Center at Stanford University, directing that institution's technology development efforts. Dr. Willis received his doctorate in Physics from Stanford University in 1996. Ronald Davis, Ph.D Professor Davis is the Director of the Stanford Genome Technology Center and Professor of Biochemistry and Genetics at the Stanford University School of Medicine and co-founder of ParAllele. He is a world-renowned researcher in the area of genomics and high throughput biochemical techniques. He pioneered many of the early techniques developed using recombinant DNA and helped conceive of novel methods for genetic linkage analysis. He has received multiple awards for his contributions to the field and sits on the NIH Genome Research Committee. In addition to his work in academia, Professor Davis has been involved in the spin-off of multiple start up companies in the area of genomics from his laboratory at Stanford. André F. Marion André Marion was one of the founders of Applied Biosystems, Inc. He served as Chairman, Chief Executive Officer and President for several years until the company's merger with Perkin Elmer Corporation. In 1995 he retired from the Perkin Elmer Corporation as the President of its Applied Biosystems Division. Prior to the founding of Applied Biosystems, Mr. Marion held various research and development management positions with Hewlett-Packard Corporation. Mr. Marion currently serves as a director on the boards of several companies, including Aclara BioSciences, Corp., Molecular Devices Corp., Cygnus, Inc. and Applied Imaging Corp. A native of France, he holds an engineering degree from the French Ecole Nationale Supérieures d'Ingénieurs Arts et Métiers in both mechanical and electronic engineering. Camille Samuels Camille Samuels is a Managing Director at Versant Ventures. Prior to Versant, Camille was a director of business development at Tularik Inc. where she was responsible for corporate strategy and developing partnerships around clinical/preclinical therapeutic programs. She also led Tularik's Technology Acquisition Group, a group that was charged with retaining the company's technological advantage. Before Tularik, Camille helped develop the business and marketing plan for the Predictive Medicine division of Millennium Pharmaceuticals. She also worked in strategy and business development for Genzyme Corporation. Jonathan MacQuitty, Ph.D. Jonathan MacQuitty became President and Director of the Abingworth's US subsidiary, Abingworth Management Inc, in 1999. He is based at the firm's offices in Palo Alto, California. Following an MA in chemistry at Oxford University and a PhD at the University of Sussex, he completed an MBA at Stanford. He held management positions at Genencor and Genentech before, in 1988, he co-founded GenPharm International as its CEO. He moved into venture capital in 1997 and has served on the Board of the Biotechnology Industry Organisation and is a Director of a number of biotech companies. Bill Ericson Bill Ericson is a general partner with Mohr, Davidow Ventures (MDV). Mr. Ericson was a founder of Rosetta Inpharmatics and served on the company's Board until its acquisition by Merck in 2001. He joined MDV after 10 years of working with and investing in entrepreneurs and early stage companies, most recently as managing partner and founder of Venture Law Group's Seattle office. Mr. Ericson currently serves on the boards of several private software and life sciences infrastructure companies. He received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law. Gregory Went, Ph.D. Gregory Went co-founded CuraGen Corporation in 1992. Dr. Went oversaw the financing and reduction to practice of the initial technology platform, and developed the first scalable processes and informatics system. Later he spearheaded both the business development, private and public financing efforts. He left in 1999 and spent a year at DNA Sciences as their COO and Director. Dr. Went received his PhD in Chemical Engineering from UC Berkeley and is the author of 20 papers and inventor on 15 patents. top^
	All site contents Copyright © 2001-2005 ParAllele BioScience, Inc. All rights reserved. • Terms of Use • Privacy Policy

The ParAllele Advantage

People

Board of Directors
Scientific Advisory Board
Management Team

History

News

Events

Alliances

Board of Directors

Thomas D. Willis, CSO and co-founder
Dr. Willis has spearheaded ParAllele's successful licensing and financing activities since the company's founding. Prior to founding ParAllele, Dr. Willis served as Associate Director of the Stanford Genome Technology Center at Stanford University, directing that institution's technology development efforts. Dr. Willis received his doctorate in Physics from Stanford University in 1996.

Ronald Davis, Ph.D
Professor Davis is the Director of the Stanford Genome Technology Center and Professor of Biochemistry and Genetics at the Stanford University School of Medicine and co-founder of ParAllele. He is a world-renowned researcher in the area of genomics and high throughput biochemical techniques. He pioneered many of the early techniques developed using recombinant DNA and helped conceive of novel methods for genetic linkage analysis. He has received multiple awards for his contributions to the field and sits on the NIH Genome Research Committee. In addition to his work in academia, Professor Davis has been involved in the spin-off of multiple start up companies in the area of genomics from his laboratory at Stanford.

André F. Marion
André Marion was one of the founders of Applied Biosystems, Inc. He served as Chairman, Chief Executive Officer and President for several years until the company's merger with Perkin Elmer Corporation. In 1995 he retired from the Perkin Elmer Corporation as the President of its Applied Biosystems Division. Prior to the founding of Applied Biosystems, Mr. Marion held various research and development management positions with Hewlett-Packard Corporation. Mr. Marion currently serves as a director on the boards of several companies, including Aclara BioSciences, Corp., Molecular Devices Corp., Cygnus, Inc. and Applied Imaging Corp. A native of France, he holds an engineering degree from the French Ecole Nationale Supérieures d'Ingénieurs Arts et Métiers in both mechanical and electronic engineering.

Camille Samuels
Camille Samuels is a Managing Director at Versant Ventures. Prior to Versant, Camille was a director of business development at Tularik Inc. where she was responsible for corporate strategy and developing partnerships around clinical/preclinical therapeutic programs. She also led Tularik's Technology Acquisition Group, a group that was charged with retaining the company's technological advantage. Before Tularik, Camille helped develop the business and marketing plan for the Predictive Medicine division of Millennium Pharmaceuticals. She also worked in strategy and business development for Genzyme Corporation.

Jonathan MacQuitty, Ph.D.
Jonathan MacQuitty became President and Director of the Abingworth's US subsidiary, Abingworth Management Inc, in 1999. He is based at the firm's offices in Palo Alto, California. Following an MA in chemistry at Oxford University and a PhD at the University of Sussex, he completed an MBA at Stanford. He held management positions at Genencor and Genentech before, in 1988, he co-founded GenPharm International as its CEO. He moved into venture capital in 1997 and has served on the Board of the Biotechnology Industry Organisation and is a Director of a number of biotech companies.

Bill Ericson
Bill Ericson is a general partner with Mohr, Davidow Ventures (MDV). Mr. Ericson was a founder of Rosetta Inpharmatics and served on the company's Board until its acquisition by Merck in 2001. He joined MDV after 10 years of working with and investing in entrepreneurs and early stage companies, most recently as managing partner and founder of Venture Law Group's Seattle office. Mr. Ericson currently serves on the boards of several private software and life sciences infrastructure companies. He received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law.

Gregory Went, Ph.D.
Gregory Went co-founded CuraGen Corporation in 1992. Dr. Went oversaw the financing and reduction to practice of the initial technology platform, and developed the first scalable processes and informatics system. Later he spearheaded both the business development, private and public financing efforts. He left in 1999 and spent a year at DNA Sciences as their COO and Director. Dr. Went received his PhD in Chemical Engineering from UC Berkeley and is the author of 20 papers and inventor on 15 patents.

top^